Development · 1 Oct 2026

Linux Laboratories has secured USD 70 million in equity capital from ChrysCapital and Tata Capital Healthcare Fund III.

4 publishers have reported this development. Each act of reporting is below, cited.

The record

expresspharma.in moneycontrol.com30 Sep 2026

ChrysCapital will acquire a significant minority stake in Chennai-based Linux Laboratories, which secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III.

indiatimes.com30 Sep 2026

Linux Laboratories Pvt. Ltd raised $70 million from ChrysCapital and Tata Capital Healthcare Fund III.

livemint.com30 Sep 2026

Tata Capital

₹319.30

▼ -2.64%

Close (EOD), as of 1 Oct 2026 · source

Tata Capital: results, dividends, orders, the full cited record →

More on Tata Capital

Sarosh Amaria, MD, Tata Capital Housing Finance Limited, explained that in an ideal situation, using retirement savings to pay off a home loan makes sense.

27 Sep 2026 · 1 publisher

Diversified NBFCs such as Tata Capital, Aditya Birla Capital, L&T Finance and Godrej Capital have entered the gold loan space either through acquisition of smaller players or branch expansion.

14 Sep 2026 · 1 publisher

Tata Capital acquired a controlling stake in Kerala-based Yogloans, Godrej Capital bought the gold loan business of Kanakadurga Finance, and Aditya Birla Capital announced plans to build a dedicated gold loan franchise with 1,000 branches.

22 Aug 2026 · 1 publisher

Tata Capital led a $30 million funding round in Tenet Diagnostics, an integrated diagnostics platform with over 35 diagnostic centres across 14 states.

18 Aug 2026 · 1 publisher

Tata Capital Healthcare Fund and Blue Earth Capital announced a $30 million investment in Tenet Diagnostics for an undisclosed equity stake.

18 Aug 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.